LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Yau, T, Park, J W, Finn, R S, Cheng, A-L, Mathurin, P, Edeline, J, Kudo, M, Han, K-H, Harding, J J, Merle, P, Rosmorduc, O, Wyrwicz, L, Schott, E, Choo, S P, Kelley, R K, Begic, D, Chen, G, Neely, J,Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz394.029
Date:
October, 2019
File:
PDF, 85 KB
2019
File converter
More search results
More benefits 
